CLN2 disease
Scope
Date
~
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Asan Medical Center to establish digestive disease hospital in Dubai
Asan Medical Center announced plans on Thursday to establish a 65-bed gastrointestinal specialized hospital in Dubai Healthcare City in Dubai, UAE, ...
Jun 23, 2023 (Gmt+09:00)
-
Korean startups
Bredis Healthcare, Tilda win June D.Day, Korea’s oldest startup pitch race
An early-stage startup by young entrepreneurs who developed a digital diagnostic tool for brain disease and an AI-powered business optimization prog...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets approval to sell biosimilar in Europe
South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Economy
S.Korea’s chronic disease: Decline in youth employment
The number of young workers in South Korea fell for a sixth straight month in April to its lowest point in more than two years, deepening concerns t...
May 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong to transfer techs for autoimmune disease to US pharma
South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...
Apr 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, UK firm to jointly develop autoimmune disease drug
South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada
Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...
Mar 06, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma introduces candidates for treating blood coagulation disease
South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based...
Mar 02, 2023 (Gmt+09:00)
-
Healthcare
Daesang Wellife signs contract with RexSoft for healthcare platform
South Korea's Daesang Wellife Corp. has inked a 2 billion won ($1.5 million) investment contract with local healthcare data science company RexSoft ...
Feb 15, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N's GERD drug K-CAB gets approval in Mexico
South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...
Feb 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanall Biopharma invests in Interon Labs for brain disease treatments
South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...
Feb 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Humasis participates Dubai MEDLAB Middle East 2023
South Korean medical devices maker, Humasis Co., is participating in the MEDLAB Middle East 2023 event taking place at the Dubai World Trade Center ...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Biomedics gets approval for Parkinson's disease clinical trials
South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clin...
Jan 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Bigsome Bio signs tech transfer agreement with university
Bigsome Bio, a subsidiary of Lotte Chilsung Beverage, has begun research on functional materials for respiratory health.The company said on Friday t...
Dec 20, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biotech firm Noul signs MOU with disease center of Ghana
South Korea's Medical diagnostics company Noul Co., Ltd. said on Monday that it has signed a memorandum of understanding with the Ghana Infectious D...
Dec 12, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ partners with Emmyon to develop ingredients preventing muscle atrophy
South Korean food giant CJ CheilJedang Corp. announced on Tuesday that it has signed a license contract with Emmyon, an American biotechnology start...
Dec 06, 2022 (Gmt+09:00)
-
Bio & Pharma
Orion to enter dental disease treatment sector
Orion Corp., the Korean company, best known for its signature product choco pie, is entering drug development. Instead of indirectly running a joint...
Nov 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Pharma companies jump into $3 bn pet care market
South Korean pharmaceutical companies are jumping into the animal medicine and diagnostics market to target the rapidly growing pet care market, whi...
Jun 24, 2022 (Gmt+09:00)